Journal of Cancer Research and Therapeutics

REVIEW ARTICLE
Year
: 2016  |  Volume : 12  |  Issue : 3  |  Page : 1109--1113

Radioiodine as an adjuvant therapy and its role in follow-up of differentiated thyroid cancer


S Padma, P Shanmuga Sundaram 
 Department of Nuclear Medicine and PET CT, Amrita Institute of Medical Sciences, Cochin, Kerala, India

Correspondence Address:
S Padma
Department of Nuclear Medicine and PET CT, Amrita Institute of Medical Sciences, Cochin - 680 2041, Kerala
India

Papillary and follicular cancers of thyroid are the most common varieties of differentiated thyroid cancers exhibiting excellent long-term prognosis when carefully managed. Being a slow-growing malignancy, guidelines exist on the staging, preoperative risk stratification, and management of these cancers to increase the overall survival of these patients. Radioactive iodine has a central role in differentiated thyroid malignancies. It has the same physical properties as stable iodine, thus both normal and malignant thyrocytes cannot differentiate radioactive from stable iodine. Differentiated thyroid carcinoma (DTC) cells concentrate cytocidal amounts of Iodine -131 (131 I) by trapping (the function of the sodium iodine symporter, or NIS) and organifying the iodide ion to produce levothyroxine and triiodothyronine. We shall discuss the role of radioiodine in the management and followup of DTC patients.


How to cite this article:
Padma S, Sundaram P S. Radioiodine as an adjuvant therapy and its role in follow-up of differentiated thyroid cancer.J Can Res Ther 2016;12:1109-1113


How to cite this URL:
Padma S, Sundaram P S. Radioiodine as an adjuvant therapy and its role in follow-up of differentiated thyroid cancer. J Can Res Ther [serial online] 2016 [cited 2017 Jul 28 ];12:1109-1113
Available from: http://www.cancerjournal.net/article.asp?issn=0973-1482;year=2016;volume=12;issue=3;spage=1109;epage=1113;aulast=Padma;type=0